Brazil and Nigeria are emerging as important export destinations for Indian pharmaceutical companies at a time of global economic uncertainty, according to data released by the commerce ministry.
Nigeria ranked among the fastest-growing markets during the first eight months of the current financial year, adding USD 179 million in exports and accounting for over 14 per cent of India’s overall pharmaceutical export growth. Exports to Brazil also rose sharply, increasing by nearly USD 100 million during the April-November period of FY26.
“These markets reflect rising healthcare access, expanding public procurement, and growing reliance on Indian generics, reinforcing India's role as a preferred supplier to high growth demand intensive regions,” a commerce ministry official said.
Also read: Indian pharmaceutical exports ranked 11th in 2023
India’s total pharmaceutical exports increased by 6.5 per cent to USD 20.48 billion during April-November 2025-26, the data showed.
The United States remained India’s single largest export destination, accounting for more than 31 per cent of pharmaceutical exports during the period. However, officials noted that demand was broadening across multiple geographies, enhancing the resilience of India’s export basket.
Alongside the US, countries such as France, the Netherlands, Canada, Germany and South Africa recorded steady growth, contributing meaningfully to export expansion while maintaining stable market shares.
Notably, exports to the Netherlands increased by over USD 58 million, underscoring India’s deeper integration into European pharmaceutical distribution networks.
“This combination of scale markets and diversified secondary destinations highlights a balanced export architecture, where growth is supported by both mature healthcare systems and fast expanding emerging economies,” the official added.
Follow us
